×
About 132,800 results

ALLMedicine™ Type 2 Diabetes Center

Research & Reviews  42,496 results

Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recomm...
https://doi.org/10.1001/jama.2021.12531
JAMA , Davidson KW et. al.

Aug 25th, 2021 - An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes...

Systematic Review and Meta-Analysis of Diabetes Knowledge among Type 2 Diabetes Patient...
https://doi.org/10.1900/RDS.2021.17.82
The Review of Diabetic Studies : RDS; Lim PC, Rajah R et. al.

Dec 3rd, 2021 - OBJECTIVE: Recognition of patient baseline knowledge is important in educating patients with type 2 diabetes mellitus (T2D) to manage their disease effectively. The purpose of this study is to review current evidence on the level of diabetes knowl...

Clinical Features, Biochemical Profile, and Response to Standard Treatment in Lean, Nor...
https://doi.org/10.1900/RDS.2021.17.68
The Review of Diabetic Studies : RDS; Faraz A, Ashraf H et. al.

Dec 3rd, 2021 - BACKGROUND: Much evidence is available on the relationship between type 2 diabetes mellitus (T2D) and obesity, but less on T2D in lean individuals. AIM: This study was conducted in 12,069 T2D patients from northern India to find out which clinical...

The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria a...
https://doi.org/10.2215/CJN.07340521
Clinical Journal of the American Society of Nephrology : ... Waijer SW, Gansevoort RT et. al.

Dec 3rd, 2021 - Atrasentan reduces the risk of kidney failure but increases the risk of edema and, possibly, heart failure. Patients with severe CKD may obtain greater absolute kidney benefits from atrasentan but may also be at higher risk of heart failure. We as...

ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinic...
https://doi.org/10.1136/bmjopen-2021-049650
BMJ Open; McCafferty K, Hollowood Z et. al.

Dec 3rd, 2021 - COVID-19, caused by SARS-CoV-2, remains a global pandemic that has affected more than 100 million people worldwide with over 4.8 million deaths as of October 2021. Patients with diabetes have both an increased susceptibility to SARS-CoV-2 infectio...

see more →

Guidelines  53 results

Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recomm...
https://doi.org/10.1001/jama.2021.12531
JAMA , Davidson KW et. al.

Aug 25th, 2021 - An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes...

Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation St...
https://doi.org/10.1001/jama.2021.11922
JAMA , Davidson KW et. al.

Aug 11th, 2021 - Gestational diabetes is diabetes that develops during pregnancy. Prevalence of gestational diabetes in the US has been estimated at 5.8% to 9.2%, based on traditional diagnostic criteria, although it may be higher if more inclusive criteria are us...

Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary ...
https://doi.org/10.1016/j.numecd.2021.04.014
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Chiodini I, Gaudio A et. al.

Jun 2nd, 2021 - Bone fragility is increasingly recognized as a relevant complication of type 2 diabetes (T2D) and diabetic patients with fragility fractures have higher mortality rates than non diabetic individuals or diabetic patients without fractures. However,...

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 9th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES...
https://doi.org/10.1016/j.numecd.2020.08.021
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Moghetti P, Balducci S et. al.

Oct 2nd, 2020 - Regular exercise is considered a cornerstone in the management of type 2 diabetes mellitus (T2DM). It improves glucose control and cardiovascular risk factors, contributes to weight loss, and also improves general well-being, likely playing a role...

see more →

Drugs  1,402 results see all →

Clinicaltrials.gov  2,654 results

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
https://clinicaltrials.gov/ct2/show/NCT04770532

Nov 25th, 2021 - This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken we...

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04591626

Nov 25th, 2021 - The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Ty...
https://clinicaltrials.gov/ct2/show/NCT04880850

Nov 25th, 2021 - This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken we...

Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT04924777

Nov 25th, 2021 - To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more si...

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
https://clinicaltrials.gov/ct2/show/NCT05134662

Nov 25th, 2021 - This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in overweight and obese su...

see more →

News  6,484 results

Retinopathy risk in children higher in T2D than T1D
https://www.mdedge.com/endocrinology/article/249370/diabetes/retinopathy-risk-children-higher-t2d-t1d
Caleb Rans, PharmD

Dec 2nd, 2021 - Children diagnosed with type 2 diabetes (T2D) appear significantly more likely to develop retinopathy and other ocular complications over time than children who are diagnosed with type 1 diabetes (T1D), researchers report. Patricia Bai Among a pop.

Diabetes Risk Higher for Transwomen vs Cisgender Females
https://www.medpagetoday.com/endocrinology/diabetes/95937

Nov 30th, 2021 - Transwomen may face a higher risk for developing type 2 diabetes than cisgender women, a new study suggested. In a review of new data from the Study of Transition Outcomes and Gender (STRONG) cohort, transwomen had a 30% higher odds of prevalent t...

Continuous Ketone Monitoring Has Potential to Cut DKA in Diabetes
https://www.medscape.com/viewarticle/963120

Nov 17th, 2021 - The development of an on-body continuous ketone monitor (CKM) is seen as potentially helpful for the prevention of diabetic ketoacidosis (DKA) and other clinical situations. Speakers at two meetings held this month have addressed the potential use...

Europe Gives Green Light to Once-Weekly Semaglutide for Weight Loss
https://www.medscape.com/viewarticle/963027

Nov 16th, 2021 - Once-weekly semaglutide 2.4 mg injection (Wegovy, Novo Nordisk) has been granted a positive opinion in the European Union for weight management in people with obesity or those who are overweight with one or more weight-related conditions. The spec...

Call for Tighter LDL Targets for Highest Risk Patients
https://www.medscape.com/viewarticle/962914

Nov 15th, 2021 - LONDON - Tighter low-density lipoprotein (LDL) targets, should be the aim in very high-risk patients, using a combination of therapies in a new era of ‘ones not twos’ (in terms of mmol/L), according to experts in lipid and cardiovascular risk mana...

see more →

Patient Education  31 results see all →